Table 2.
Clearly stated aim | Inclusion of consecutive patients | Prospective data collection | Endpoints appropriate to study aim | Unbiased assessment of study endpoint | Follow-up appropriate to study aim | < 5% Lost to follow up | Prospective calculation of study size | Adequate control group | Contemporary groups |
Baseline equivalence of groups | Adequate statistical analyses | TOTAL MINORS SCORE | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jaffer et al. [29] | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 0 | NA | NA | NA | NA | 10/16 |
Kim et al. [27] | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 1 | 2 | 15/24 |
Lin et al. [21] | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | NA | NA | NA | NA | 8/16 |
Liao et al. [22] | 2 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | 2 | 1 | 2 | 2 | 16/24 |
Abdelrahman et al. [31] | 2 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | NA | NA | NA | NA | 9/16 |
Kim et al. [23] | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | NA | NA | NA | NA | 8/16 |
Mán et al. [24] | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 16/24 |
Brown et al. [32] | 2 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | NA | NA | NA | NA | 9/16 |
Kim et al. [30] | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 1 | 2 | 2 | 1 | 2 | 18/24 |
Lee et al. [25] | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 1 | 2 | 15/24 |
Ussia et al. [26] | 2 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 16/24 |
Angeramo et al. [28] | 2 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | NA | NA | NA | NA | 9/16 |
Kubat et al. [20] | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 0 | 2 | 2 | 1 | 2 | 17/24 |